{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:26:19Z","timestamp":1794047179086,"version":"4.8.0"},"reference-count":191,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2020-07062"],"award-info":[{"award-number":["2020-07062"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jconrel.2025.114466","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:39:07Z","timestamp":1764088747000},"page":"114466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Targeted therapeutics for IBD unraveling the potential of stimulus-responsive nanoparticles"],"prefix":"10.1016","volume":"389","author":[{"given":"Andreia S.","family":"Barros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rute","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Sarmento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.114466_bb0005","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7247238","article-title":"A comprehensive review and update on the pathogenesis of inflammatory bowel disease","volume":"2019","author":"Guan","year":"2019","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.jconrel.2025.114466_bb0010","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","article-title":"Understanding and preventing the global increase of inflammatory bowel disease","volume":"152","author":"Kaplan","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2025.114466_bb0015","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Brown Ng","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2025.114466_bb0020","first-page":"1","article-title":"Global evolution of inflammatory bowel disease across epidemiologic stages","author":"Hracs","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.114466_bb0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11894-019-0705-6","article-title":"Evolving epidemiology of IBD","volume":"21","author":"Windsor","year":"2019","journal-title":"Curr. Gastroenterol. Rep."},{"key":"10.1016\/j.jconrel.2025.114466_bb0030","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2025.114466_bb0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/ecco-jcc\/jjz187","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: surgical treatment","volume":"14","author":"Adamina","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.jconrel.2025.114466_bb0040","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.addr.2020.07.010","article-title":"Advanced nanomedicines for the treatment of inflammatory diseases","volume":"157","author":"Brusini","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.114466_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040622319899297","article-title":"Emerging treatments for inflammatory bowel disease","volume":"11","author":"Hazel","year":"2020","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.jconrel.2025.114466_bb0050","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/00365521.2018.1563805","article-title":"The future of nanomedicine in optimising the treatment of inflammatory bowel disease","volume":"54","author":"Mohan","year":"2019","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0055","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3390\/ijms24021526","article-title":"Pathophysiology of inflammatory bowel disease: innate immune system","volume":"24","author":"Saez","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.114466_bb0060","series-title":"Inflammatory Bowel Disease: Pathogenesis, Diagnosis and Management","author":"Rajapakse","year":"2021"},{"key":"10.1016\/j.jconrel.2025.114466_bb0065","first-page":"1","article-title":"The genetics of inflammatory bowel disease","author":"El Hadad","year":"2023","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.jconrel.2025.114466_bb0070","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.3748\/wjg.v12.i23.3668","article-title":"Family and twin studies in inflammatory bowel disease","volume":"12","author":"Halme","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0075","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/gut.29.7.990","article-title":"Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking","volume":"29","author":"Tysk","year":"1988","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2025.114466_bb0080","first-page":"1428","article-title":"Heritability in inflammatory bowel disease: from the first twin study to genome-wide association studies","volume":"21","author":"Gordon","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2025.114466_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104892","article-title":"Genetics and epigenetics of IBD","volume":"159","author":"Annese","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jconrel.2025.114466_bb0090","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/JIR.S137606","article-title":"NOD2 and inflammation: current insights","author":"Negroni","year":"2018","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.jconrel.2025.114466_bb0095","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences","volume":"126","author":"Loftus","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2025.114466_bb0100","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1126\/science.1208344","article-title":"Linking long-term dietary patterns with gut microbial enterotypes","volume":"334","author":"Wu","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2025.114466_bb0105","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/ajg.2011.44","article-title":"Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature","volume":"106","author":"Hou","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0110","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/jwh.1997.6.49","article-title":"The nurses\u2019 health study: 20-year contribution to the understanding of health among women","volume":"6","author":"Colditz","year":"1997","journal-title":"J. Womens Health"},{"key":"10.1016\/j.jconrel.2025.114466_bb0115","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1038\/ajg.2010.192","article-title":"Animal protein intake and risk of inflammatory bowel disease: the E3N prospective study","volume":"105","author":"Jantchou","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0120","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/ecco-jcc\/jjac054","article-title":"Meat intake is associated with a higher risk of ulcerative colitis in a large European prospective cohort study\u00f8","volume":"16","author":"Dong","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.jconrel.2025.114466_bb0125","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.gastro.2019.04.016","article-title":"Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses","volume":"157","author":"Piovani","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2025.114466_bb0130","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/00054725-200411000-00019","article-title":"Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications","volume":"10","author":"Birrenbach","year":"2004","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2025.114466_bb0135","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2017.05.010","article-title":"Genetic factors interact with tobacco smoke to modify risk for inflammatory bowel disease in humans and mice","volume":"153","author":"Yadav","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2025.114466_bb0140","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/apt.13511","article-title":"Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn\u2019s disease","volume":"43","author":"N. To","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2025.114466_bb0145","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s00384-019-03441-9","article-title":"Role of environmental factors in the pathogenesis of Crohn\u2019s disease: a critical review","volume":"34","author":"Chen","year":"2019","journal-title":"Int. J. Color. Dis."},{"key":"10.1016\/j.jconrel.2025.114466_bb0150","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3389\/fped.2019.00432","article-title":"Stress triggers flare of inflammatory bowel disease in children and adults","volume":"7","author":"Sun","year":"2019","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.jconrel.2025.114466_bb0155","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.gtc.2017.08.006","article-title":"The brain-gut axis and stress in inflammatory bowel disease","volume":"46","author":"Bernstein","year":"2017","journal-title":"Gastroenterol. Clin."},{"key":"10.1016\/j.jconrel.2025.114466_bb0160","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1053\/j.gastro.2013.02.038","article-title":"Stress-induced corticotropin-releasing hormone-mediated NLRP6 inflammasome inhibition and transmissible enteritis in mice","volume":"144","author":"Sun","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2025.114466_bb0165","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/00054725-200608000-00005","article-title":"Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys","volume":"12","author":"Fuller-Thomson","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2025.114466_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.733992","article-title":"The gut microbiota in inflammatory bowel disease","volume":"12","author":"Qiu","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0175","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3390\/pathogens8030126","article-title":"Alteration of gut microbiota in inflammatory bowel disease (IBD): cause or consequence? IBD treatment targeting the gut microbiome","volume":"8","author":"Khan","year":"2019","journal-title":"Pathogens"},{"key":"10.1016\/j.jconrel.2025.114466_bb0180","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/imm.12950","article-title":"Segmented filamentous bacteria-induced immune responses: a balancing act between host protection and autoimmunity","volume":"154","author":"Flannigan","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.jconrel.2025.114466_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00639","article-title":"The Treg\/Th17 axis: a dynamic balance regulated by the gut microbiome","volume":"6","author":"Omenetti","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0190","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1126\/science.1145697","article-title":"Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid","volume":"317","author":"Mucida","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2025.114466_bb0195","doi-asserted-by":"crossref","first-page":"12204","DOI":"10.1073\/pnas.0909122107","article-title":"Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota","volume":"107","author":"Round","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2025.114466_bb0200","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3748\/wjg.v20.i5.1165","article-title":"Intestinal barrier in inflammatory bowel disease","volume":"20","author":"Antoni","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0205","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1007\/s10620-013-2694-x","article-title":"Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease","volume":"58","author":"Rana","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.jconrel.2025.114466_bb0210","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4161\/gmic.20529","article-title":"Activated fluid transport regulates bacterial-epithelial interactions and significantly shifts the murine colonic microbiome","volume":"3","author":"Keely","year":"2012","journal-title":"Gut Microbes"},{"key":"10.1016\/j.jconrel.2025.114466_bb0215","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.nano.2015.02.018","article-title":"Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue","volume":"11","author":"Hua","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.114466_bb0220","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/gut.35.3.353","article-title":"Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis","volume":"35","author":"Pullan","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2025.114466_bb0225","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/ibd.20993","article-title":"Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis","volume":"15","author":"Braun","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2025.114466_bb0230","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/MCG.0b013e3182688e73","article-title":"Mucin function in inflammatory bowel disease: an update","volume":"47","author":"Boltin","year":"2013","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0235","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1053\/j.gastro.2020.08.005","article-title":"Increased intestinal permeability is associated with later development of Crohn\u2019s disease","volume":"159","author":"Turpin","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2025.114466_bb0240","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5217\/ir.2015.13.1.11","article-title":"Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases","volume":"13","author":"Lee","year":"2015","journal-title":"Intest. Res."},{"key":"10.1016\/j.jconrel.2025.114466_bb0245","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.gastro.2005.05.002","article-title":"Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution","volume":"129","author":"Heller","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2025.114466_bb0250","first-page":"164","article-title":"Colon drug delivery systems for the treatment of inflammatory bowel disease","volume":"2","author":"Qelliny","year":"2019","journal-title":"J. Adv. Biomed. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.114466_bb0255","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.48.4.571","article-title":"Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs","volume":"48","author":"Nugent","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2025.114466_bb0260","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijpharm.2018.12.074","article-title":"Advances in orally-delivered pH-sensitive nanocarrier systems; an optimistic approach for the treatment of inflammatory bowel disease","volume":"558","author":"Zeeshan","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.114466_bb0265","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ibd.20539","article-title":"Intestinal barrier dysfunction in inflammatory bowel diseases","volume":"15","author":"McGuckin","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2025.114466_bb0270","article-title":"Treatment of inflammatory bowel disease: a comprehensive review","volume":"8","author":"Cai","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.jconrel.2025.114466_bb0275","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.autrev.2019.03.002","article-title":"Induction and maintenance treatment of inflammatory bowel disease: a comprehensive review","volume":"18","author":"Jeong","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jconrel.2025.114466_bb0280","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2165\/11584820-000000000-00000","article-title":"Cost effectiveness of treatments for inflammatory bowel disease","volume":"29","author":"Bodger","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jconrel.2025.114466_bb0285","doi-asserted-by":"crossref","first-page":"113","DOI":"10.25122\/jml-2018-0075","article-title":"A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease","volume":"12","author":"Seyedian","year":"2019","journal-title":"J. Med. Life"},{"key":"10.1016\/j.jconrel.2025.114466_bb0290","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/ibd\/izy327","article-title":"A state-of-the-art review of new and emerging therapies for the treatment of IBD","volume":"25","author":"Chudy-Onwugaje","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2025.114466_bb0295","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41395-018-0416-x","article-title":"Bridging medical and surgical treatment of inflammatory bowel disease: the role of interventional IBD","volume":"114","author":"Shen","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0300","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3390\/jcm9051273","article-title":"Revisiting inflammatory bowel disease: pathology, treatments, challenges and emerging therapeutics including drug leads from natural products","volume":"9","author":"Yeshi","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2025.114466_bb0305","first-page":"CD000543","article-title":"Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis","volume":"8","author":"Murray","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2025.114466_bb0310","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000354699","article-title":"Risks of inflammatory bowel disease treatment with glucocorticosteroids and aminosalicylates","volume":"31","author":"Curkovic","year":"2013","journal-title":"Dig. Dis."},{"key":"10.1016\/j.jconrel.2025.114466_bb0315","first-page":"CD003715","article-title":"Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn\u2019s disease","volume":"9","author":"Akobeng","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2025.114466_bb0320","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1172\/JCI992","article-title":"Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B","volume":"101","author":"Wahl","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2025.114466_bb0325","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1179\/135100010X12826446921707","article-title":"Scavenging of reactive oxygen and nitrogen species by the prodrug sulfasalazine and its metabolites 5-aminosalicylic acid and sulfapyridine","volume":"15","author":"Couto","year":"2010","journal-title":"Redox Rep."},{"key":"10.1016\/j.jconrel.2025.114466_bb0330","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3904\/kjim.2022.132","article-title":"Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-\u03b1","volume":"37","author":"Park","year":"2022","journal-title":"Korean J. Intern. Med."},{"key":"10.1016\/j.jconrel.2025.114466_bb0335","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncpgasthep0696","article-title":"Drug insight: aminosalicylates for the treatment of IBD","volume":"4","author":"Nielsen","year":"2007","journal-title":"Nat. Clin. Pract. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0340","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2036.2002.01151.x","article-title":"A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis","volume":"16","author":"Mansfield","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2025.114466_bb0345","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ecco-jcc\/jjaa053","article-title":"The historical role and contemporary use of corticosteroids in inflammatory bowel disease","volume":"14","author":"Dorrington","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.jconrel.2025.114466_bb0350","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3399\/bjgp18X699341","article-title":"Using corticosteroids appropriately in inflammatory bowel disease: a guide for primary care","volume":"68","author":"Barrett","year":"2018","journal-title":"Br. J. Gen. Pract."},{"key":"10.1016\/j.jconrel.2025.114466_bb0355","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s10620-015-3897-0","article-title":"Budesonide multi-matrix for the treatment of patients with ulcerative colitis","volume":"61","author":"Lichtenstein","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.jconrel.2025.114466_bb0360","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000443127","article-title":"When to start immunomodulators in inflammatory bowel disease?","volume":"34","author":"Sharara","year":"2016","journal-title":"Dig. Dis."},{"key":"10.1016\/j.jconrel.2025.114466_bb0365","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.3390\/jcm12216742","article-title":"The role of pharmacogenetics in the therapeutic response to Thiopurines in the treatment of inflammatory bowel disease: A systematic review","volume":"12","author":"Ribeiro","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2025.114466_bb0370","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5217\/ir.2020.00155","article-title":"Use of thiopurines in inflammatory bowel disease: an update","volume":"20","author":"Singh","year":"2022","journal-title":"Intest. Res."},{"key":"10.1016\/j.jconrel.2025.114466_bb0375","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/gutjnl-2019-320185","article-title":"Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn\u2019s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource","volume":"70","author":"Stournaras","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2025.114466_bb0380","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/ibd.21221","article-title":"Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts","volume":"16","author":"Jharap","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2025.114466_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100271","article-title":"Efficacy and safety of methotrexate in the management of inflammatory bowel disease: a systematic review and meta-analysis of randomized, controlled trials","volume":"20","author":"Nielsen","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jconrel.2025.114466_bb0390","first-page":"CD003459","article-title":"Methotrexate for induction of remission in refractory Crohn\u2019s disease","volume":"4","author":"Alfadhli","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2025.114466_bb0395","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn\u2019s disease","volume":"342","author":"Feagan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.114466_bb0400","first-page":"CD006618","article-title":"Methotrexate for induction of remission in ulcerative colitis","volume":"8","author":"Chande","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2025.114466_bb0405","first-page":"CD007560","article-title":"Methotrexate for maintenance of remission in ulcerative colitis","volume":"8","author":"Wang","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2025.114466_bb0410","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1053\/j.gastro.2018.06.046","article-title":"Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis","volume":"155","author":"Herfarth","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2025.114466_bb0415","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/14712598.2020.1708896","article-title":"Is there room for immunomodulators in ulcerative colitis?","volume":"20","author":"Chhibba","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.jconrel.2025.114466_bb0420","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2025.114466_bb0425","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/apt.13862","article-title":"Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab","volume":"45","author":"Ungar","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2025.114466_bb0430","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/MIB.0000000000000589","article-title":"Use of methotrexate in the treatment of inflammatory bowel diseases","volume":"22","author":"Herfarth","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2025.114466_bb0435","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/0016-5085(95)90384-4","article-title":"European trial of cyclosporine in chronic active Crohn's disease: a 12-month study","volume":"109","author":"E.F. Stange, R. Modigliani, A.S. Pe\u00f1a, A.J. Wood, G. Feutren, P.R. Smith, E.S. Group","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2025.114466_bb0440","series-title":"Crohn's Disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach","first-page":"421","article-title":"Calcineurin inhibitors in ulcerative colitis","author":"Fischer","year":"2017"},{"key":"10.1016\/j.jconrel.2025.114466_bb0445","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2009.03.012","article-title":"Calcineurin inhibitors in oral medicine","volume":"61","author":"Al Johani","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0450","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00535-010-0352-z","article-title":"The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease","volume":"46","author":"Naganuma","year":"2011","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0455","first-page":"14","article-title":"Janus kinase inhibitors for the management of patients with inflammatory bowel disease","volume":"18","author":"Sedano","year":"2022","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0460","doi-asserted-by":"crossref","first-page":"11322","DOI":"10.3390\/ijms222111322","article-title":"The era of Janus kinase inhibitors for inflammatory bowel disease treatment","volume":"22","author":"Kim","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.114466_bb0465","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/13543784.2018.1492547","article-title":"Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials","volume":"27","author":"D\u2019Amico","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jconrel.2025.114466_bb0470","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2147\/CEG.S150908","article-title":"Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy","author":"Tran","year":"2019","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.jconrel.2025.114466_bb0475","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.114466_bb0480","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2025.114466_bb0485","series-title":"Remicade (infliximab)","author":"Agency","year":"2014"},{"key":"10.1016\/j.jconrel.2025.114466_bb0490","first-page":"CD003574","article-title":"Tumor necrosis factor-alpha antibody for induction of remission in Crohn\u2019s disease","volume":"4","author":"Akobeng","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2025.114466_bb0495","article-title":"Infliximab in inflammatory bowel disease","volume":"10","author":"Papamichael","year":"2019","journal-title":"Ther. Adv. Chron. Dis."},{"key":"10.1016\/j.jconrel.2025.114466_bb0500","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti\u2013tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2025.114466_bb0505","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1053\/j.gastro.2011.06.054","article-title":"Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis","volume":"141","author":"Colombel","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2025.114466_bb0510","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.cgh.2012.12.042","article-title":"Long-term outcome of perianal fistulizing Crohn\u2019s disease treated with infliximab","volume":"11","author":"Bouguen","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0515","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/j.gastro.2005.01.048","article-title":"Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn\u2019s disease","volume":"128","author":"Lichtenstein","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2025.114466_bb0520","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/apt.12284","article-title":"The role of anti-TNF in the management of ulcerative colitis\u2013past, present and future","volume":"37","author":"Danese","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2025.114466_bb0525","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti\u2013tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2025.114466_bb0530","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2025.114466_bb0535","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/ajg.2014.242","article-title":"Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3","volume":"109","author":"Colombel","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0540","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ajg.2011.60","article-title":"Loss of response and need for adalimumab dose intensification in Crohn\u2019s disease: a systematic review","volume":"106","author":"Billioud","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0545","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing anti-TNF treatments in inflammatory bowel disease","volume":"13","author":"Ben-Horin","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jconrel.2025.114466_bb0550","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/apt.12940","article-title":"Adalimumab dose escalation is effective for managing secondary loss of response in Crohn\u2019s disease","volume":"40","author":"Ma","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2025.114466_bb0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-230X-14-80","article-title":"Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience","volume":"14","author":"Yamada","year":"2014","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0560","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1097\/MIB.0000000000000208","article-title":"Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD","volume":"20","author":"van Schaik","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2025.114466_bb0565","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41390-020-01177-9","article-title":"The role of integrins in inflammation and angiogenesis","volume":"89","author":"Mezu-Ndubuisi","year":"2021","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.jconrel.2025.114466_bb0570","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/CEG.S293272","article-title":"Anti-integrins for the treatment of inflammatory bowel disease: current evidence and perspectives","author":"Gubatan","year":"2021","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.jconrel.2025.114466_bb0575","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.3389\/fimmu.2018.01700","article-title":"Effects of anti-integrin treatment with vedolizumab on immune pathways and cytokines in inflammatory bowel diseases","volume":"9","author":"Rath","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0580","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/apt.14167","article-title":"One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study","volume":"46","author":"Amiot","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2025.114466_bb0585","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.114466_bb0590","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.114466_bb0595","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/CEG.S429039","article-title":"Magnetic resonance Enterography assessment of transmural healing with Vedolizumab in moderate to severe Crohn\u2019s disease: feasibility in the VERSIFY phase 3 clinical trial","author":"Rimola","year":"2024","journal-title":"Clin. Exp. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0600","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.3748\/wjg.v24.i23.2457","article-title":"Vedolizumab for inflammatory bowel disease: from randomized controlled trials to real-life evidence","volume":"24","author":"Scribano","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0605","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","article-title":"Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial","volume":"384","author":"Vermeire","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2025.114466_bb0610","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1007\/s12325-020-01366-2","article-title":"Etrolizumab for the treatment of ulcerative colitis and Crohn\u2019s disease: an overview of the phase 3 clinical program","volume":"37","author":"Sandborn","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jconrel.2025.114466_bb0615","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.2174\/13894501113146660229","article-title":"Anti-IL-12\/23 in Crohn\u2019s disease: bench and bedside","volume":"14","author":"Niederreiter","year":"2013","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.jconrel.2025.114466_bb0620","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/00365521.2014.993700","article-title":"New targeted therapies such as anti-adhesion molecules, anti-IL-12\/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease","volume":"50","author":"Bravata","year":"2015","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0625","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11894-021-00829-y","article-title":"Immunomodulatory agents for treatment of patients with inflammatory bowel disease (review safety of anti-TNF, anti-integrin, anti IL-12\/23, JAK inhibition, sphingosine 1-phosphate receptor modulator, azathioprine\/6-MP and methotrexate)","volume":"23","author":"Sattler","year":"2021","journal-title":"Curr. Gastroenterol. Rep."},{"key":"10.1016\/j.jconrel.2025.114466_bb0630","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-year efficacy and safety of ustekinumab treatment in Crohn\u2019s disease: the IM-UNITI trial","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0635","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.114466_bb0640","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1080\/17460441.2021.1961740","article-title":"How can we improve peptide drug discovery? Learning from the past","volume":"16","author":"Craik","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.114466_bb0645","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/cbdd.12055","article-title":"The future of peptide-based drugs","volume":"81","author":"Craik","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.jconrel.2025.114466_bb0650","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.drudis.2021.01.022","article-title":"Converting peptides into drugs targeting intracellular protein\u2013protein interactions","volume":"26","author":"Philippe","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2025.114466_bb0655","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.imlet.2017.01.004","article-title":"The dual role of cathelicidins in systemic inflammation","volume":"182","author":"da Silva","year":"2017","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.jconrel.2025.114466_bb0660","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.tube.2014.09.007","article-title":"Effect of 1, 25-dihydroxy vitamin D3 on cathelicidin expression in patients with and without cavitary tuberculosis","volume":"94","author":"Afsal","year":"2014","journal-title":"Tuberculosis"},{"key":"10.1016\/j.jconrel.2025.114466_bb0665","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/35106587","article-title":"Innate antimicrobial peptide protects the skin from invasive bacterial infection","volume":"414","author":"Nizet","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.114466_bb0670","first-page":"799","article-title":"A new role for cathelicidin in ulcerative colitis in mice","volume":"232","author":"Tai","year":"2007","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.jconrel.2025.114466_bb0675","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.3390\/ijms19092714","article-title":"Peptides as therapeutic agents for inflammatory-related diseases","volume":"19","author":"La Manna","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.114466_bb0680","first-page":"R45","article-title":"Biological function and clinical relevance of chromogranin A and derived peptides, Endocr","volume":"3","author":"D'amico","year":"2014","journal-title":"Connect"},{"key":"10.1016\/j.jconrel.2025.114466_bb0685","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01131","article-title":"Chromofungin ameliorates the progression of colitis by regulating alternatively activated macrophages","volume":"8","author":"Eissa","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0690","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.3748\/wjg.v27.i47.8138","article-title":"Impact of intrarectal chromofungin treatment on dendritic cells-related markers in different immune compartments in colonic inflammatory conditions","volume":"27","author":"Kapoor","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0695","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1053\/gast.2000.16489","article-title":"Enteroendocrine localization of GLP-2 receptor expression in humans and rodents","volume":"119","author":"Yusta","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2025.114466_bb0700","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.1073\/pnas.93.15.7911","article-title":"Induction of intestinal epithelial proliferation by glucagon-like peptide 2","volume":"93","author":"Drucker","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2025.114466_bb0705","doi-asserted-by":"crossref","first-page":"G211","DOI":"10.1152\/ajpgi.00530.2006","article-title":"Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2","volume":"293","author":"Sigalet","year":"2007","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0710","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1053\/jpsu.2000.6861","article-title":"Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2","volume":"35","author":"Alavi","year":"2000","journal-title":"J. Pediatr. Surg."},{"key":"10.1016\/j.jconrel.2025.114466_bb0715","first-page":"2884","article-title":"In vivo and in vitro degradation of glucagon-like peptide-2 in humans","volume":"85","author":"Hartmann","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2025.114466_bb0720","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1021\/acs.jmedchem.5b01909","article-title":"Synthesis and pharmacological characterization of novel glucagon-like peptide-2 (GLP-2) analogues with low systemic clearance","volume":"59","author":"Wi\u015bniewski","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.114466_bb0725","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/0091270009342252","article-title":"Population pharmacokinetics of teduglutide following repeated subcutanenous administrations in healthy participants and in patients with short bowel syndrome and Crohn\u2019s disease","volume":"50","author":"Marier","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0730","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11010-010-0678-0","article-title":"The role of glucagon-like peptide-2 on apoptosis, cell proliferation, and oxidant\u2013antioxidant system at a mouse model of intestinal injury induced by tumor necrosis factor-alpha\/actinomycin D","volume":"350","author":"Arda-Pirincci","year":"2011","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.jconrel.2025.114466_bb0735","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/ibd.21117","article-title":"Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn\u2019s disease","volume":"16","author":"A.L. Buchman, S. Katz, J.C. Fang, C.N. Bernstein, S.G. Abou-Assi, T.S. Group","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2025.114466_bb0740","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11605-020-04832-y","article-title":"Declining rates of surgery for inflammatory bowel disease in the era of biologic therapy","volume":"25","author":"Lowe","year":"2021","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.jconrel.2025.114466_bb0745","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s13304-020-00719-4","article-title":"Modern surgery for ulcerative colitis","volume":"72","author":"Murphy","year":"2020","journal-title":"Updates Surg."},{"key":"10.1016\/j.jconrel.2025.114466_bb0750","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.3748\/wjg.14.2678","article-title":"Surgery for inflammatory bowel disease","volume":"14","author":"Hwang","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0755","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1007\/s10350-007-0240-7","article-title":"The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review","volume":"50","author":"Cornish","year":"2007","journal-title":"Dis. Colon Rectum"},{"key":"10.1016\/j.jconrel.2025.114466_bb0760","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.surg.2004.06.018","article-title":"Fertility is reduced after restorative proctocolectomy with ileal pouch anal anastomosis: a study of 300 patients","volume":"136","author":"Gorgun","year":"2004","journal-title":"Surgery"},{"key":"10.1016\/j.jconrel.2025.114466_bb0765","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bpg.2018.05.017","article-title":"Surgery in ulcerative colitis: when? How?","volume":"32","author":"Gallo","year":"2018","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0770","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.amjsurg.2015.12.027","article-title":"Current challenges in the surgical management of Crohn\u2019s disease: a systematic review","volume":"212","author":"Schlussel","year":"2016","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.jconrel.2025.114466_bb0775","doi-asserted-by":"crossref","DOI":"10.1093\/gastro\/goac070","article-title":"Post-operative prevention and monitoring of Crohn\u2019s disease recurrence","volume":"10","author":"Lee","year":"2022","journal-title":"Gastroenterol. Rep."},{"key":"10.1016\/j.jconrel.2025.114466_bb0780","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jconrel.2020.12.034","article-title":"Nanomedicines accessible in the market for clinical interventions","volume":"330","author":"Gadekar","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114466_bb0785","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41551-021-00698-w","article-title":"The evolution of commercial drug delivery technologies","volume":"5","author":"Vargason","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2025.114466_bb0790","doi-asserted-by":"crossref","DOI":"10.1142\/S1793984413430010","article-title":"Nanomaterials for protein-mediated therapy and delivery","volume":"3","author":"Barry","year":"2013","journal-title":"Nano Life"},{"key":"10.1016\/j.jconrel.2025.114466_bb0795","first-page":"1","article-title":"An overview of drug delivery systems","author":"Jain","year":"2020","journal-title":"Drug\u00a0Deliv\u00a0Syst"},{"key":"10.1016\/j.jconrel.2025.114466_bb0800","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jconrel.2016.06.016","article-title":"Nanoparticles for oral delivery: design, evaluation and state-of-the-art","volume":"240","author":"Date","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114466_bb0805","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.addr.2016.03.011","article-title":"How to design the surface of peptide-loaded nanoparticles for efficient oral bioavailability?","volume":"106","author":"Malhaire","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.114466_bb0810","first-page":"742","article-title":"Progress in nanomedicine: approved and investigational nanodrugs","volume":"42","author":"Ventola","year":"2017","journal-title":"P. T."},{"key":"10.1016\/j.jconrel.2025.114466_bb0815","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.3748\/wjg.v23.i23.4200","article-title":"Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: effects in an in vivo model","volume":"23","author":"Dianzani","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2021.112123","article-title":"Enhancing stability and anti-inflammatory properties of curcumin in ulcerative colitis therapy using liposomes mediated colon-specific drug delivery system","volume":"151","author":"Wang","year":"2021","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0825","doi-asserted-by":"crossref","first-page":"8875","DOI":"10.2147\/IJN.S210315","article-title":"Nanoparticle-mediated drug delivery systems for the treatment of IBD: current perspectives","author":"Yang","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.114466_bb0830","series-title":"Stimuli-Responsive Polymeric Nanoparticles for cancer Therapy","first-page":"27","author":"Lale","year":"2018"},{"key":"10.1016\/j.jconrel.2025.114466_bb0835","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/cmdc.201402290","article-title":"Stimuli-responsive polymeric nanoparticles for nanomedicine","volume":"10","author":"Crucho","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jconrel.2025.114466_bb0840","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201700141","article-title":"ROS-responsive polyprodrug nanoparticles for triggered drug delivery and effective cancer therapy","volume":"29","author":"Xu","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.114466_bb0845","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.biomaterials.2016.08.010","article-title":"A superoxide dismutase\/catalase mimetic nanomedicine for targeted therapy of inflammatory bowel disease","volume":"105","author":"Zhang","year":"2016","journal-title":"Biomater"},{"key":"10.1016\/j.jconrel.2025.114466_bb0850","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.msec.2016.11.030","article-title":"Internal stimuli-responsive nanocarriers for drug delivery: design strategies and applications","volume":"71","author":"Liu","year":"2017","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.jconrel.2025.114466_bb0855","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.addr.2012.01.020","article-title":"Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications","volume":"64","author":"Fleige","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.114466_bb0860","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.actbio.2014.11.017","article-title":"Therapeutic efficacy of quercetin enzyme-responsive nanovesicles for the treatment of experimental colitis in rats","volume":"13","author":"Castangia","year":"2015","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2025.114466_bb0865","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1517\/17425247.2013.736962","article-title":"Eudragit\u00ae: a technology evaluation","volume":"10","author":"Thakral","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2025.114466_bb0870","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2025.2544689","article-title":"Advances in oral treatment of inflammatory bowel disease using protein-based nanoparticle drug delivery systems","volume":"32","author":"Lin","year":"2025","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2025.114466_bb0875","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijpharm.2014.07.009","article-title":"Pr\u00e9at, pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease","volume":"473","author":"Beloqui","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.114466_bb0880","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jconrel.2014.03.039","article-title":"Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases","volume":"183","author":"Ali","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114466_bb0885","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1517\/17425247.2013.821978","article-title":"pH-and ion-sensitive polymers for drug delivery","volume":"10","author":"Yoshida","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2025.114466_bb0890","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.125332","article-title":"pH-sensitive HPMCP-chitosan nanoparticles containing 5-aminosalicylic acid and berberine for oral colon delivery in a rat model of ulcerative colitis","volume":"244","author":"Mahami","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0895","first-page":"157","article-title":"Nanoparticle-based therapeutics of inflammatory bowel diseases: a narrative review of the current state and prospects","volume":"3","author":"Yang","year":"2020","journal-title":"J. BioX Res."},{"key":"10.1016\/j.jconrel.2025.114466_bb0900","first-page":"229","article-title":"A systematic review of nano formulation of natural products for the treatment of inflammatory bowel disease: drug delivery and pharmacological targets","volume":"26","author":"Taghipour","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.114466_bb0905","first-page":"2401408","article-title":"Colon enzyme-activated prebiotic nanomedicine for targeted therapy of inflammatory bowel disease","volume":"9","author":"Cao","year":"2025","journal-title":"Small Methods"},{"key":"10.1016\/j.jconrel.2025.114466_bb0910","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.123229","article-title":"Folic acid-modified lactoferrin nanoparticles coated with a laminarin layer loaded curcumin with dual-targeting for ulcerative colitis treatment","volume":"232","author":"Ye","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0915","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/bph.13428","article-title":"ROS in gastrointestinal inflammation: rescue or sabotage?","volume":"174","author":"Aviello","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0920","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.redox.2015.10.006","article-title":"Antioxidant therapy for treatment of inflammatory bowel disease: does it work?","volume":"6","author":"Moura","year":"2015","journal-title":"Redox Biol."},{"key":"10.1016\/j.jconrel.2025.114466_bb0925","article-title":"ROS-responsive nanoparticles for oral delivery of luteolin and targeted therapy of ulcerative colitis by regulating pathological microenvironment","volume":"14","author":"Tan","year":"2022","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.jconrel.2025.114466_bb0930","doi-asserted-by":"crossref","first-page":"7206","DOI":"10.1039\/D2TB00615D","article-title":"Thioether-based ROS responsive polymers for biomedical applications","volume":"10","author":"Criado-Gonzalez","year":"2022","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2025.114466_bb0935","article-title":"Orally delivered stimulus-sensitive nanomedicine to harness teduglutide efficacy in inflammatory bowel disease","volume":"2402502","author":"Barros","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2025.114466_bb0940","doi-asserted-by":"crossref","first-page":"113948","DOI":"10.1016\/j.jconrel.2025.113948","article-title":"Oral delivery of tunable oxidation-responsive budesonide-loaded nanoparticles enhances inflammation modulation in intestinal colitis","volume":"384","author":"Cristelo","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114466_bb0945","article-title":"Mechanistic investigation on oxidative degradation of ROS-responsive thioacetal\/thioketal moieties and their implications","volume":"1","author":"Liu","year":"2020","journal-title":"Cell Rep. Phys. Sci."},{"key":"10.1016\/j.jconrel.2025.114466_bb0950","doi-asserted-by":"crossref","first-page":"50692","DOI":"10.1021\/acsami.2c17827","article-title":"pH\/ROS dual-sensitive natural polysaccharide nanoparticles enhance \u201cone stone four birds\u201d effect of rhein on ulcerative colitis","volume":"14","author":"Qi","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2025.114466_bb0955","first-page":"4565","article-title":"Enhanced therapeutic efficacy of budesonide in experimental colitis with enzyme\/pH dual-sensitive polymeric nanoparticles","author":"Naeem","year":"2015","journal-title":"Int. J. Nanomedicine"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925010806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925010806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:43:51Z","timestamp":1794044631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925010806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":191,"alternative-id":["S0168365925010806"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114466","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted therapeutics for IBD unraveling the potential of stimulus-responsive nanoparticles","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114466","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114466"}}